Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials

Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials

<b>Background/Objectives:</b> Pembrolizumab, an immune checkpoint inhibitor targeting programmed death 1 (PD-1), is a widely employed therapy for various gastrointestinal (GI) cancers. We conducted a systematic review of clinical trials investigating pembrolizumab monotherapy in GI cance...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nikolas Naleid, Amit Mahipal, Sakti Chakrabarti
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Series:	Biomedicines
Subjects:	pembrolizumab safety programmed cell death receptor 1 toxicity
Online Access:	https://www.mdpi.com/2227-9059/13/1/229
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01)

Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis
by: Biqiong Pan, et al.
Published: (2025-02-01)

Successful Neoadjuvant Therapy with Pembrolizumab Monotherapy for Advanced Ascending Colon Cancer
by: Chien-Tzu Huang*, et al.
Published: (2023-07-01)

Maxillary osteonecrosis linked to Pembrolizumab therapy: a case report
by: Gosselin-Rousselle Louise, et al.
Published: (2024-01-01)

Case report: Low-dose radiation reverses pembrolizumab resistance in melanoma
by: Ka Hey Agnes Fong, et al.
Published: (2025-02-01)

Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations
by: Stewart M, et al.
Published: (2025-02-01)

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
by: Yuan Yao, et al.
Published: (2025-02-01)

An Open‐Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second‐Line Therapy for Advanced Head and Neck Squamous Cell Cancers
by: Vinod K. Ramani, et al.
Published: (2025-01-01)

Identifying factors for pembrolizumab eligibility in head and neck cancer
by: Satoru Miyamaru, et al.
Published: (2025-02-01)

Unveiling the toxicity of JWH-018 and JWH-019: Insights from behavioral and molecular studies in vivo and vitro
by: Fenghua Zhou, et al.
Published: (2025-01-01)

Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
by: Hanan R. Nada, et al.
Published: (2025-01-01)

Acute and prolonged toxicity assessment of Cannabis sativa extract in rodents and lagomorphs
by: Alana C. Costa, et al.
Published: (2025-06-01)

Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review
by: Beata Mayer, et al.
Published: (2025-12-01)

Pembrolizumab with external radiation therapy effectively controlled TMB-high unresectable recurrent parathyroid cancer: a case report with review of literature
by: Hiroshi Katoh, et al.
Published: (2024-11-01)

Successful Pregnancy Outcome in a Patient Treated with Pembrolizumab and Exposed to Fluoro-Deoxyglucose (<sup>18</sup>F-FDG) PET/CT: Case Report and Review of Literature
by: Anna Lucia Mastricci, et al.
Published: (2025-01-01)

Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01)

Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients
by: Eman Eissa, et al.
Published: (2022-01-01)

Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis
by: Xinyan Hao, et al.
Published: (2025-01-01)

Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre
by: Maria João Santos, et al.
Published: (2025-02-01)

Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer
by: Johan Staby Olsén, et al.
Published: (2025-03-01)

Predicting High-Grade Acute Urinary Toxicity and Lower Gastrointestinal Toxicity After Postoperative Volumetric Modulated Arc Therapy for Cervical and Endometrial Cancer Using a Normal Tissue Complication Probability Model
by: Tianyu Yang, et al.
Published: (2025-01-01)

Sintilimab for treating progressive multifocal leukoencephalopathy caused by human polyomavirus 2 virus infection following allogeneic hematopoietic cell transplantation: a case report
by: Xuelian Jin, et al.
Published: (2025-12-01)

Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data
by: Fabrizio Nelli, et al.
Published: (2025-01-01)

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01)

A systematic review of exposure to toxic elements and neurocognitive development in children
by: Tingyi Guo, et al.
Published: (2025-02-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

RIPK1 in necroptosis and recent progress in related pharmaceutics
by: Kunhou Yao, et al.
Published: (2025-02-01)

Toxicity of Common Indoor Household Insecticides Registered in Florida
by: Frederick M. Fishel
Published: (2019-09-01)

Toxicity of Common Indoor Household Insecticides Registered in Florida
by: Frederick M. Fishel
Published: (2019-09-01)

Advancements in Managing Anthracycline-Induced Cardiotoxicity: Insights from Interventional Clinical Trials
by: Zhao M, et al.
Published: (2025-01-01)

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives
by: Bujnak AC, et al.
Published: (2025-01-01)

Therapeutic implications for the PD-1 axis in cerebrovascular injury
by: James Feghali, et al.
Published: (2025-01-01)

Toxicity evaluation of herbicides used in sugarcane crops to Zebrafish (Danio rerio)
by: Gabrielli Aparecida Sanches Tesolin, et al.
Published: (2014-01-01)

Common Toxic Plants for Florida Horse Owners
by: Alyssa Schortinghouse, et al.
Published: (2023-02-01)

Common Hazards Associated with Sheep and Goat Feed
by: Chalise Brown, et al.
Published: (2020-12-01)

Common Hazards Associated with Sheep and Goat Feed
by: Chalise Brown, et al.
Published: (2020-12-01)

Colorimetric aptasensor coupled with a deep-learning-powered smartphone app for programmed death ligand-1 expressing extracellular vesicles
by: Adeel Khan, et al.
Published: (2025-01-01)

Urdu Toxic Comment Classification With PURUTT Corpus Development
by: Hafiz Hassaan Saeed, et al.
Published: (2025-01-01)

Toxic effects and mechanisms of nanoplastics and sulfonamide antibiotics on Scenedesmus obliquus
by: Jianyuan Yang, et al.
Published: (2025-01-01)

Role of Computed Tomography in Predicting Programmed Death Ligand-1 Positivity in Gastric Adenocarcinoma
by: Yu ZH, et al.
Published: (2025-02-01)